A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugsByBruce GilUpdatedMarch 27, 2024
A month's supply of the weight loss drug Ozempic costs less than $5 to make, study saysByBruce GilUpdatedMarch 27, 2024
The FDA has approved Merck's drug to treat a rare, deadly lung diseaseByQuartz StaffPublishedMarch 26, 2024
Johnson & Johnson is reportedly eyeing its second big heart device company acquisitionByBruce GilUpdatedMarch 26, 2024
Ozempic maker Novo Nordisk gets more weight loss drug competition as a rival releases promising dataByBruce GilPublishedMarch 26, 2024
Ozempic maker Novo Nordisk just made a $1 billion bet — but not on weight loss drugsByBruce GilUpdatedMarch 25, 2024
The weight loss drug race has Amgen coming for Novo Nordisk and Eli LillyByFrancisco VelasquezUpdatedMarch 24, 2024
Medicare is covering Wegovy, a new $4 million drug, and AstraZeneca bets $2 billion: pharma news round upByBruce GilPublishedMarch 23, 2024
AstraZeneca is betting $2 billion on next-generation cancer treatmentsByBruce GilUpdatedMarch 19, 2024
AstraZeneca will cap the cost of its widely used inhalers at $35 a monthByMatt Novak / GizmodoPublishedMarch 19, 2024
The rise of Ozempic maker Novo Nordisk to one of the world's most valuable companiesByBruce GilUpdatedMarch 17, 2024
Amazon gets in on it, a pill more powerful than Ozempic, and some competition: Weight loss drugs roundupByBruce GilPublishedMarch 16, 2024
Novo Nordisk's weight loss drug Wegovy could soon be covered by MedicareByBruce GilUpdatedMarch 15, 2024
